This series of promotional meetings has been developed by AstraZeneca and OmniaMed SB. AstraZeneca has fully funded the meetings and is responsible for the content, logistics, and selection of speakers. OmniaMed SB has provided support. This Primary Care meeting is intended for HCPs in the following roles only:  Doctors, Nurses, Specialist Nurses, Pharmacists, Dietitians, NHS Medicines Management and Clinical Commissioning professionals. This invitation is non-transferable to any other HCP roles.

Partnering for progress in type 2 diabetes: Exploring patient engagement in primary care

2018 Dates

Cardiff

(Download Calendar Invite)

7 June 2018
Cardiff Marriott Hotel

Glasgow 

(Download Calendar Invite)

12 June 2018
Glasgow Marriott Hotel

Birmingham 

 (Download Calendar Invite)

13 June 2018
Holiday Inn Birmingham Airport 

London 

(Download Calendar Invite)

3 July 2018
Prospero House, London Bridge

Newcastle

(Download Calendar Invite)

10 July 2018
Gateshead Marriott Hotel

 

Results from the 2016–17 National Diabetes Audit (NDA) in England and Wales indicate that the management of type 2 diabetes remains sub-optimal.1 For example, less than half of people with type 2 diabetes received the eight care processes that NICE recommends are performed annually; and around one third of people with type 2 diabetes failed to achieve the NICE-recommended HbA1c treatment target of ≤58 mmol/mol(≤7.5%).1 Patient engagement is increasingly regarded as a key factor in the improvement of health behaviors and outcomes in chronic diseases, such as type 2 diabetes.2 Most people with type 2 diabetes receive their diabetes care in primary care3, where interactions with healthcare professionals can provide opportunities to encourage engagement in their healthcare4.

Through a mixture of presentations, interactive case studies and discussions with expert speakers, this series of full-day meetings is designed to help clinicians enhance their diabetes care. The morning will be spent examining patient engagement, and how applying psychology, language and communication skills can help to foster this. In the afternoon we will look at considerations for selecting glucose-lowering therapy options for people with type 2 diabetes, including the sodium-glucose co-transporter 2 inhibitor (SGLT2i) dapagliflozin. We will finish by reflecting on the day’s learning; this will also provide an opportunity for attendees to put any burning questions they have to our session speakers.

Applicability to practice is a key consideration for these meetings. We have therefore designed a workbook with templates for reflective learning to help you meet your revalidation and CPD requirements.

We look forward to welcoming you at your nearest meeting for what promises to be a stimulating and practical agenda relevant to healthcare professionals working with people with type 2 diabetes in primary care.